SG11202100776SA - Novel transcription activator - Google Patents

Novel transcription activator

Info

Publication number
SG11202100776SA
SG11202100776SA SG11202100776SA SG11202100776SA SG11202100776SA SG 11202100776S A SG11202100776S A SG 11202100776SA SG 11202100776S A SG11202100776S A SG 11202100776SA SG 11202100776S A SG11202100776S A SG 11202100776SA SG 11202100776S A SG11202100776S A SG 11202100776SA
Authority
SG
Singapore
Prior art keywords
transcription activator
novel transcription
novel
activator
transcription
Prior art date
Application number
SG11202100776SA
Other languages
English (en)
Inventor
Tetsuya Yamagata
Yuanbo Qin
Original Assignee
Modalis Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modalis Therapeutics Corp filed Critical Modalis Therapeutics Corp
Publication of SG11202100776SA publication Critical patent/SG11202100776SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
SG11202100776SA 2018-08-07 2019-08-06 Novel transcription activator SG11202100776SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862715432P 2018-08-07 2018-08-07
PCT/JP2019/030972 WO2020032057A1 (fr) 2018-08-07 2019-08-06 Nouvel activateur de transcription

Publications (1)

Publication Number Publication Date
SG11202100776SA true SG11202100776SA (en) 2021-02-25

Family

ID=69413502

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100776SA SG11202100776SA (en) 2018-08-07 2019-08-06 Novel transcription activator

Country Status (13)

Country Link
US (1) US20210332094A1 (fr)
EP (1) EP3833758A4 (fr)
JP (1) JP2021533742A (fr)
KR (1) KR20210040985A (fr)
CN (1) CN112585266A (fr)
AU (1) AU2019317066A1 (fr)
BR (1) BR112021002231A2 (fr)
CA (1) CA3107268A1 (fr)
IL (1) IL280478A (fr)
MX (1) MX2021001525A (fr)
SG (1) SG11202100776SA (fr)
WO (1) WO2020032057A1 (fr)
ZA (1) ZA202100991B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020085441A1 (ja) * 2018-10-24 2021-09-16 株式会社モダリス 改変されたＣａｓ９タンパク質及びその用途
WO2021230385A1 (fr) 2020-05-15 2021-11-18 Astellas Pharma Inc. Procédé de traitement de la dystrophie musculaire par ciblage d'un gène utrophine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028168A1 (fr) * 2000-10-03 2002-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Systeme d"expression de genes regulables a haut rendement
US8106255B2 (en) 2002-01-23 2012-01-31 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
EP2510096B2 (fr) 2009-12-10 2018-02-07 Regents of the University of Minnesota Modification de l'adn induite par l'effecteur tal
US10266850B2 (en) 2012-05-25 2019-04-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
CN111471675A (zh) * 2014-03-05 2020-07-31 国立大学法人神户大学 特异性转变靶向dna序列的核酸碱基的基因组序列的修饰方法、及其使用的分子复合体
CN108271384B (zh) * 2015-09-09 2022-04-15 国立大学法人神户大学 用于特异性转变靶向dna序列的核酸碱基的革兰氏阳性菌的基因组序列的转变方法、及其使用的分子复合体
WO2018035503A1 (fr) * 2016-08-18 2018-02-22 The Regents Of The University Of California Ingénierie génomique de crispr-cas par l'intermédiaire d'un système d'administration d'aav modulaire
US11674138B2 (en) * 2017-03-13 2023-06-13 President And Fellows Of Harvard College Methods of modulating expression of target nucleic acid sequences in a cell
KR20210093954A (ko) * 2018-11-16 2021-07-28 아스텔라스세이야쿠 가부시키가이샤 유트로핀 유전자를 표적으로 하여 근이영양증을 치료하는 방법

Also Published As

Publication number Publication date
US20210332094A1 (en) 2021-10-28
WO2020032057A1 (fr) 2020-02-13
AU2019317066A1 (en) 2021-02-18
BR112021002231A2 (pt) 2021-05-04
ZA202100991B (en) 2023-12-20
IL280478A (en) 2021-03-01
EP3833758A1 (fr) 2021-06-16
JP2021533742A (ja) 2021-12-09
EP3833758A4 (fr) 2022-05-18
CA3107268A1 (fr) 2020-02-13
CN112585266A (zh) 2021-03-30
MX2021001525A (es) 2021-04-19
KR20210040985A (ko) 2021-04-14

Similar Documents

Publication Publication Date Title
EP3353156A4 (fr) Inhibiteurs de l'autopalmitoylation du facteur de transcription tead
IL269196A (en) New inhibitors
GB2601077B (en) Audio circuitry
EP3447058A4 (fr) Nouvel inhibiteur de la ss-lactamase à spectre large
GB201803568D0 (en) Novel compounds and uses
EP3207639A4 (fr) Tonalité de signalisation inaudible
IL280913A (en) New methods
EP3596086A4 (fr) Inhibiteurs de mk2, leur synthèse et leurs intermédiaires
EP3210969A4 (fr) Activateur des canaux kcnq2-5
GB201805453D0 (en) Novel use
IL280912A (en) New methods
IL289589A (en) New methods
EP3801527A4 (fr) Nouvelles méthodes
SG11202005711TA (en) Novel uses
EP3765021A4 (fr) Nouveaux procédés
IL280478A (en) Copy operator
GB201903229D0 (en) Immunotherapy
IL282396A (en) new uses
GB201706519D0 (en) Height-adustable aerobic step
IL267692A (en) Activator of nrf2
GB201910873D0 (en) Novel uses
PL3647404T3 (pl) Bioreaktor
GB201911762D0 (en) Novel methods
GB201911764D0 (en) Novel Methods
GB201901043D0 (en) Novel methods